Moderna

MRNA US Health Care Biotechnology
S&P 500
$143.97
+5.38%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.09.
  • Current assets comfortably cover current liabilities (current ratio 3.29).

!Watch-points

  • Return on equity is on the lower side at -41.7%.
  • Return on capital employed is on the lower side at -34.3%.
  • The company reported a net loss in the latest period.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
9.7

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Piotroski F-ScoreWeak
3 / 8

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 8 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$57.48B
Current Price$ 143.97
High / Low$ 176.66 / 22.28
Stock P/E-19.83
Book Value$ 16.99
Dividend Yield0%
ROCE-34.25%
ROE-41.74%
Debt to Equity0.09
Current Ratio3.29
P/B Ratio8.496312
EPS$ -7.26
Debt$590.00M
PAT Margin-145.16%
Cash PAT$-2.61B
Educational data only. Not a recommendation to buy, sell or hold any security.